Moteur de recherche d’entreprises européennes
Financement de l’UE (4 067 745 €) : Interactions protéine-excipient et interactions protéine-protéine dans la formulation Hor 11/08/2015 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
Interactions protéine-excipient et interactions protéine-protéine dans la formulation
The revolution of biotechnology has led to the creation of various types of therapeutic biologics with the potential to provide treatment for new chronic and malignant diseases. Though the potential advantages of biologics lay in their high specificity and potency combined with few side effects, their formulation still remains a large challenge to pharmaceutical scientists. This is in part due to the complex, not-well understood relationship between the physicochemical properties of proteins and formulation conditions required for protein stability. A comprehensive understanding of the molecular mechanisms behind protein stabilization and solubility would provide the formulation scientists with knowledge of the interplay between formulation and stability that in turn could potentially make formulation development faster, cheaper and less labour intensive than the currently used broad screening approach. Understanding the susceptibilities of formulations to protein aggregation and denaturation can reduce the response time to for instance product failure. Few universities in Europe have formulation of biologics as a scientific subject. Consequently, the pharmaceutical industry is forced to train scientists - a challenge for larger companies, and an insurmountable task for smaller companies. Scientists in the field of structural biology, biophysics, protein formulation and stability have formed a consortium to systematically map physicochemical properties of biologics, formulation conditions and protein stability. The main objective of the consortium is to provide a new generation of innovative and entrepreneurial early-stage researchers that will develop methodologies, tools and databases to guide the formulation of robust biologics. The consortium will not only provide an excellent platform to train a new generation of formulation scientists, but also establish avenues for designing new formulation strategies and thereby securing the leading edge of EU expertise.
| Max IV Laboratory, Lund University | ? |
| Danmarks Tekniske Universitet | 580 164 € |
| Kobenhavns Universitet | 290 082 € |
| Ludwig-Maximilians-Universitaet Muenchen | 747 649 € |
| Lunds Universitet | 527 319 € |
| Medimmune Ltd. | 546 576 € |
| Novozymes A/S | 580 164 € |
| The University of Manchester | 546 576 € |
| Wyatt Technology Europe GmbH | 249 216 € |
https://cordis.europa.eu/project/id/675074
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel. L’état actuel est présenté à la page suivante : Max IV Laboratory, Lund University, Lund, Suède.